Prodrug, laninamivir octanoate, a long-Acting neuraminidase inhibitor, using an easy-to-use inhaler in healthy volunteers

Journal of Bioequivalence and Bioavailability

Volumn 3, Issue 1, 2011, Pages 001-004

  Yoshiba, Satoshi ^a   Okabe, Hiromi ^a   Ishizuka, Hitoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

CS 8958; Human; Laninamivir; Laninamivir octanoate; Neuraminidase inhibitor; Pharmacokinetics; Safety

Indexed keywords

LANINAMIVIR; LANINAMIVIR OCTANOATE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79952345497     PISSN: None     EISSN: 09750851     Source Type: Journal    
DOI: 10.4172/jbb.1000048     Document Type: Article

References (19)

1. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA (2010) Drugs in development for influenza. Drugs 70: 1349-1362.
2. Frederick G. Hayden, M.D., Albert D.M.E. Osterhaus, D.V.M., Ph.D., John J, et al. (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Eng J Med 337: 874-880.
3. Frederick G. Hayden, M.D., Larisa V. Gubareva, Ph.D., Arnold S. Monto, M.D, et al. (2000) Inhaled zanamivir for the prevention of Influenza in families. N Engl J Med 343:1282-1289.
4. Honda T, Kubo S, Masuda T, Arai M, Kobayashi Y, et al. (2009) Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-Omethyl- Neu5Ac2en. Bio org Med Chem Lett 19: 2901-3144.
5. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K (2010) Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 50: 1319-1329.
6. Ishizuka H, Yoshiba S, Yoshihara K, Okabe H. (2011) Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its prodrug, CS-8958. J Clin Pharmacol 51: 243-251.
7. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1027.
8. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, et al. (2010) Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 6: e1000786.
9. Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, et al. (2009) CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in mouse respiratory tract. Antimicrob Agents Chemother 53: 4845-4851.
10. Koyama K, Takahashi M, Nakai N, Takakusa H, Murai T, et al. (2010) Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats. Xenobiotica 54:1256-1254.
11. LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, et al. (2007) Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 29:1579-1590.
12. Mitchell J, Nagel M (2003) Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations. J Aerosol Med 16: 341-377.
13. Mitchell J, Newman S, Chan K (2007) In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review. AAPS PharmSciTech 8: E1- E12.
14. Newman S, Wilding I, Hirst P (2000) Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 208: 49-60.
15. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
16. Son YJ, McConville J (2008) Advancements in dry powder delivery to the lung. Drug Development and Industrial Pharmacy 34: 948-959.
17. Sugaya N, Ohashi Y (2010) Long-acting neuraminidase inhibitor laninamivir octanoate (LO) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 54:2575-2582.
18. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, et al. (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51: 1167-1175.
19. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, et al. (2009) LO, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting antiinfluenza virus activity. Antimicrob Agents Chemother 53: 186-192.